Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy.
作者信息
Montopoli M, Zorzi M, Cocetta V, Prayer-Galetti T, Guzzinati S, Bovo E, Rugge M, Calcinotto A
机构信息
Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy; VIMM-Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Veneto Tumour Registry, Azienda Zero, Padova, Italy.
出版信息
Ann Oncol. 2021 May;32(5):676-677. doi: 10.1016/j.annonc.2021.01.069. Epub 2021 Jan 29.
Abstract
摘要
相似文献
1
Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy.接受抗雌激素治疗的乳腺癌和卵巢癌患者感染新型冠状病毒2的临床结局
Ann Oncol. 2021 May;32(5):676-677. doi: 10.1016/j.annonc.2021.01.069. Epub 2021 Jan 29.
2
Estrogen and COVID-19: friend or foe?雌激素与新型冠状病毒肺炎：是友还是敌？
Ann Oncol. 2021 Jul;32(7):933-934. doi: 10.1016/j.annonc.2021.03.201. Epub 2021 Mar 29.
3
The Impact of COVID-19 Infection During the Postoperative Period After Surgery for Ovarian Cancer.COVID-19 感染对卵巢癌术后患者的影响。
In Vivo. 2022 May-Jun;36(3):1337-1341. doi: 10.21873/invivo.12835.
4
Challenges and management options of tubo-ovarian cancer in the midst of SARS-CoV-2 pandemic.2019冠状病毒病大流行期间输卵管卵巢癌的挑战与管理选择
Eur J Surg Oncol. 2020 Nov;46(11):2160-2161. doi: 10.1016/j.ejso.2020.06.043. Epub 2020 Jun 30.
5
Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic.在 COVID-19 大流行期间接受化疗、生物治疗、内分泌治疗或主动监测的乳腺癌患者的结局。
Oncologist. 2022 Mar 4;27(2):89-96. doi: 10.1093/oncolo/oyab042.
6
Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach.COVID-19 对乳腺癌的影响：从分子机制到治疗方法。
Curr Pharm Biotechnol. 2023;24(2):238-252. doi: 10.2174/1389201023666220421133311.
7
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.COVID-19 与卵巢癌：探索静脉（IV）治疗以外的替代方案。
Gynecol Oncol. 2020 Jul;158(1):34-36. doi: 10.1016/j.ygyno.2020.04.703. Epub 2020 Apr 29.
8
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.奥拉帕利（AZD2281）联合抗血管生成药物西地尼布（AZD2171）治疗复发性上皮性卵巢癌或三阴性乳腺癌的 1 期临床试验。
Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.
9
Ovarian Cancer Biomarkers in the COVID-19 Era.COVID-19 时代的卵巢癌生物标志物。
Int J Environ Res Public Health. 2023 May 29;20(11):5994. doi: 10.3390/ijerph20115994.
10
[Complex oncologic therapy for loco-regionally advanced breast cancer associated with long-lasting SARS-CoV-2 PCR-positivity].[针对与长期SARS-CoV-2 PCR阳性相关的局部晚期乳腺癌的综合肿瘤治疗]
Orv Hetil. 2021 Apr 7;162(16):611-614. doi: 10.1556/650.2021.32192.
引用本文的文献
1
Retrospective Analysis of the Effect of Postmenopausal Women Medications on SARS-CoV-2 Infection Progression.绝经后女性药物对新型冠状病毒感染进展影响的回顾性分析
Life (Basel). 2024 Sep 3;14(9):1107. doi: 10.3390/life14091107.
2
Sex hormones in COVID-19 severity: The quest for evidence and influence mechanisms.COVID-19 严重程度中的性激素：证据和影响机制的探索。
J Cell Mol Med. 2024 Jun;28(12):e18490. doi: 10.1111/jcmm.18490.
3
Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review.睾酮抑制联合高剂量雌激素作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的潜在治疗方法。一篇综述。
Heliyon. 2022 Dec;8(12):e12376. doi: 10.1016/j.heliyon.2022.e12376. Epub 2022 Dec 16.
4
Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?新冠病毒易感性中的性激素：关键因素还是混杂因素？
Nat Rev Endocrinol. 2023 Apr;19(4):217-231. doi: 10.1038/s41574-022-00780-6. Epub 2022 Dec 9.
5
The SARS-CoV-2 spike protein binds and modulates estrogen receptors.SARS-CoV-2 刺突蛋白结合并调节雌激素受体。
Sci Adv. 2022 Dec 2;8(48):eadd4150. doi: 10.1126/sciadv.add4150. Epub 2022 Nov 30.
6
The SARS-CoV-2 spike protein binds and modulates estrogen receptors.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与雌激素受体结合并对其进行调节。
bioRxiv. 2022 May 23:2022.05.21.492920. doi: 10.1101/2022.05.21.492920.
7
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.描述雷洛昔芬作为一种对抗 SARS-CoV-2 及其变体的潜在药物的特性。
Cell Death Dis. 2022 May 25;13(5):498. doi: 10.1038/s41419-022-04961-z.
8
Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach.COVID-19 对乳腺癌的影响：从分子机制到治疗方法。
Curr Pharm Biotechnol. 2023;24(2):238-252. doi: 10.2174/1389201023666220421133311.
9
Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study.与 COVID-19 合并乳腺癌患者住院相关的因素：一个多元化的洛杉矶多中心队列研究。
Clin Breast Cancer. 2022 Jun;22(4):e558-e566. doi: 10.1016/j.clbc.2021.12.005. Epub 2021 Dec 17.
10
Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入蛋白血管紧张素转换酶2（ACE-2）和跨膜丝氨酸蛋白酶2（TMPRSS-2）在激素调控、衰老及心脏损伤小鼠模型中的免疫反应性
Sci Rep. 2021 Dec 14;11(1):23993. doi: 10.1038/s41598-021-03181-3.
本文引用的文献
1
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer.意大利威尼托地区的 SARS-CoV-2 感染：癌症患者的不良预后。
Nat Cancer. 2020 Aug;1(8):784-788. doi: 10.1038/s43018-020-0104-9. Epub 2020 Jul 31.
2
Impact of sex and gender on COVID-19 outcomes in Europe.欧洲 COVID-19 结局的性别差异。
Biol Sex Differ. 2020 May 25;11(1):29. doi: 10.1186/s13293-020-00304-9.
3
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).雄激素剥夺疗法治疗前列腺癌与 SARS-CoV-2 感染风险的关系：一项基于人群的研究（N=4532）。
Ann Oncol. 2020 Aug;31(8):1040-1045. doi: 10.1016/j.annonc.2020.04.479. Epub 2020 May 6.
4
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
Zotero 插件